SpringerLink
Log in

Prognostic Factors in Breast Cancer

  • Conference paper
Endocrine Therapy of Breast Cancer IV

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

New directions in research regarding adjuvant treatment of patients with early breast cancer concerns (potential) new treatment modalities and better selection of high- and low-risk patients. In the current discussion on the application of systemic adjuvant therapy in primary breast cancer, identification of high- and low-risk patients is a major issue [1]. Several classical (Table 1) and second generation prognostic factors (proliferation rate, DNA ploidy, oncogenes, growth factor receptors, and some glycoproteins) are used for making therapeutic decisions [2]. At present, more than 60 prognostic parameters have been reported and can be classified into 4 main groups: patient characteristics, blood parameters, tumour characteristics and response to therapy (Table 2).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 85.59
Price includes VAT (Germany)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
EUR 106.99
Price includes VAT (Germany)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. McGuire WL: Adjuvant treatment of node-negative breast cancer. N Engl J Med 1989 (320): 525–527

    Article  PubMed  CAS  Google Scholar 

  2. McGuire WL: Prognostic factors for recurrence and survival. In: Educational Booklet American Society of Clinical Oncology, 25th Annual Meeting 1989 pp 89–92

    Google Scholar 

  3. Tandon AK, Clark GM, Chamnes GC, Chirgwin JM, McGuire WL: Cathepsin D and prognosis in breast cancer. N Engl J Med 1990 (322):297–302

    Article  PubMed  CAS  Google Scholar 

  4. Bain RP, Greenberg RS, Whitaker JP: Racial differences in survival of women with breast cancer. J Chron Dis 1986 (39): 631–642

    Article  PubMed  CAS  Google Scholar 

  5. Russo J, Frederick J, Ownby HE, Fine G, Hussain M, Krickstein HI, Robbins TO, Rosenberg B: Predictors of recurrence and survival of patients with breast cancer. J Clin Path 1987 (88): 123–131

    CAS  Google Scholar 

  6. Foekens JA, Portengen H, van Putten WLJ, Trapman AMAC, Reubi J-C, Alexieva-Figusch J, Klijn JGM: Prognostic value of receptors for insulinlike growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 1989 (49): 7002–7009

    PubMed  CAS  Google Scholar 

  7. Alexieva-Figusch J, van Putten WLJ, Blankenstein MA, Blonk-van der Wijst J, Klijn JGM: The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer. Cancer 1988 (61): 758–768

    Article  PubMed  CAS  Google Scholar 

  8. Fourquet A, Campana F, Zafrani B, Mosseri V, Vielh P, Durane JC, Vilcoq JR: Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys 1989 (17): 719–725

    Article  PubMed  CAS  Google Scholar 

  9. Adami H-O, Malker B, Meirik O, Persson I, Bergkvist L, Stone B: Age as a prognostic factor in breast cancer. Cancer 1985 (56): 898–902

    Article  PubMed  CAS  Google Scholar 

  10. Cascinelli N, Singletary E, Greco M, Ames F, Testori A, Baldini M, Morabito A, Bufalino R, Shallenberger R, Guinee V et al: Long-term survival and prognostic factors for 2170 breast cancer patients treated at two cancer centers (Milan and Houston). Tumori 1989 (75): 123–131

    PubMed  CAS  Google Scholar 

  11. Early Breast Cancer Trialists’ Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 1988 (319): 1681–1692

    Article  Google Scholar 

  12. Beex LVAM: Metabolic diseases influencing prognosis. In: Stoll BA (ed) Breast Cancer: Treatment and Prognosis. Blackwell, Oxford 1986 pp 200–211

    Google Scholar 

  13. Beard DB, Haskell CM: Carcinoembryonic antigen in breast cancer, clinical review. Am J Med 1986 (80): 241–245

    Article  PubMed  CAS  Google Scholar 

  14. Kerin MJ, McAnena OJ, O’Malley VP, Grimes H, Given HF: CA 15-3: its relationship to clinical stage and progression to metastatic disease in breast cancer. Br J Surg 1989 (76): 838–839

    Article  PubMed  CAS  Google Scholar 

  15. llfeld D, Barzilay J, Dux Z, Ran M: Correlation of Fct receptors on peripheral blood mononuclear cells and survival in patients metastatic cancer. Breast Cancer Res Treatm 1986 (7): 181–186

    Article  Google Scholar 

  16. Holtkamp W, Nagel GE, Wander H-E, Rauschecker HF, von Heyden D: Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int J Cancer 1984 (34): 323–328

    Article  PubMed  CAS  Google Scholar 

  17. Dowsett M, McGarrick GE, Harris AL, Coombes RC, Smith IE, Jeffcoate SL: The prognostic significance of hyperprolactinaemia in breast cancer. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti)Steroidal Agents. Monograph Series of the EORTC, vol 18. Raven Press, New York 1987 pp 175–181

    Google Scholar 

  18. Alexieva-Figusch J, de Jong FH, Lamberts SWJ, Planting ASTh, van Gilse HA, Blankenstein MA, Blonk-van der Wijst J, Klijn JGM: Alternating and combined treatment with tamoxifen and progestins in postmenopausal breast cancer. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti)Steroidal Agents. Monograph Series of the EORTC, vol 18. Raven Press, New York 1987 pp 145–155

    Google Scholar 

  19. Emerman JT, Leaky M, Gout PW, Bruchovsky N: Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 1985 (17): 421– 424

    Article  PubMed  CAS  Google Scholar 

  20. Pierrepoint CG, Turkes AO, Walker KJ, Harper ME, Wilson DW, Peeling WB, Griffiths K: Endocrine factors in the treatment of prostatic cancer. In: Schroder FH, Richards B (eds) Therapeutical Principles in Metastatic Prostatic Cancer. Alan R Liss, New York 1985 pp 51 -72

    Google Scholar 

  21. Waseda N, Kato Y, Imura H, Kurata M: Prognostic value of estrogen and prolactin receptor analysis in human breast cancer. Jpn J Cancer Res 1985 (76): 517–523

    PubMed  CAS  Google Scholar 

  22. Bonneterre J, Peyrat JP, Beuscart R, Lefebvre J, Demaille A: Prognostic significance of prolactin receptors (PRL-R) in human breast cancer. Cancer Res 1987 (47): 4724–4728

    PubMed  CAS  Google Scholar 

  23. Fisher B, Redmond C, Fisher ER, Caplan R and other contributing National Surgical Adjuvant Breast and Bowel Project Investigators: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from NSABBP Project Protocol B-06. J Clin Oncol 1988 (6): 1076–1087

    PubMed  CAS  Google Scholar 

  24. Singh L, Wilson AJ, Baum M, Whimster WF, Birch IH, Jackson IM, Lowrey C, Palmer MK: The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO (“Nolvadex”) trial. Br J Cancer 1988 (57): 612–614

    Article  PubMed  CAS  Google Scholar 

  25. Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Locher GW, Reed R, Golouh R, Säve-Söderbergh J, Hollaway L, Russell I, Rudenstam CM, for the Ludwig Breast Cancer Study Group: Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 1986 (58): 2662–2670

    Article  PubMed  CAS  Google Scholar 

  26. Van der Linde JC, Lindeman J, Baak JP, Meijer CJ, Herman CJ: The multivariate prognostic index and nuclear DNA content are independent prognostic factors in primary breast cancer patients. Cytometry 1989 (10): 56–61

    Article  Google Scholar 

  27. Shek LLM, Godolphin W: Model for breast cancer survival: relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis. Cancer Res 1988 (48): 5565–5569

    PubMed  CAS  Google Scholar 

  28. Clark GM, Sledge GW, Osborne CK, McGuire WL: Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987(5): 55–61

    PubMed  CAS  Google Scholar 

  29. Coombes RC, Berger U, Mansi J, Redding H, Powles TJ, Neville AM, McKinna A, Nash AG, Gazet J-C, Ford HT, Ormerod M, McDonnell T: Prognostic significance of micrometastases in bone marrow in patients with primary breast cancer. NCI Monogr 1986(1): 51–53

    PubMed  Google Scholar 

  30. Swennerton KD, Legha SS, Smith T, Hortobagy GN, Gehan EA, Yap HY, Gutterman JU, Blumenschein GR: Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979 (39): 1552–1562

    Google Scholar 

  31. Foekens JA, Portengen H, van Putten WLJ, Peters HA, Krijnen HUM, Alexieva-Figusch J, Klijn JGM: Prognostic value of estrogen and progesterone receptors measured by enzym immunoassays in human breast cancer cytosols. Cancer Res 1989 (49): 5823–5828

    PubMed  CAS  Google Scholar 

  32. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS: Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res 1989 (49) :1052–1056

    PubMed  CAS  Google Scholar 

  33. Raemaekers JMM, Beex LVAM, Pieters GFFM, Smals AGH, Benraad ThJ, Kloppenborg PWC and the Breast Study Group: Progesterone receptor activity and relapse-free survival in patients with primary breast cancer: the role of adjuvant chemotherapy. Breast Cancer Res Treatm 1987 (9): 191–199

    Article  CAS  Google Scholar 

  34. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Aust N Z J Surg 1984 (54): 2436–2440

    CAS  Google Scholar 

  35. Colston KW, Berger U, Coombes RC: Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1989 (i): 188–191

    Article  Google Scholar 

  36. Kaufmann M, Kiesel L, Klinga K, Runnebaum B, Kubli F: Gonadotropin-releasing hormone receptors in human breast carcinoma. In: Abstractbook 4th EORTC Breast Cancer Working Conference 1987: abstr D 2.22

    Google Scholar 

  37. Fekete M, Wittliff JL, Schally AW: Characteristics and distribution of receptors for [D-Trp6]-luteinizing-hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Analysis 1989(3): 137–141

    Article  CAS  Google Scholar 

  38. Bonneterre J, Peyrat JP: Prolactin receptors (PRL-R) and breast cancer. Eur J Cancer Clin Oncol 1989 (25): 1121–1122

    Article  PubMed  CAS  Google Scholar 

  39. Ben-David M, Wittliff JL, Fekete M, Kadar T, Biran S, Schally AV: Lack of relationship between the levels of prolactin receptors and steroid receptors in women with breast cancer. Biomed Pharmacother 1988(42):327–334

    PubMed  CAS  Google Scholar 

  40. Pekonen F, Partanen S, Mäkinen T, Rutanen E-M: Receptors for epidermal growth factor and insulinlike growth factor 1 and their relation to steroid receptors in human breast cancer. Cancer Res 1988 (48): 1343–1347

    PubMed  CAS  Google Scholar 

  41. Peyrat J-P, Bonneterre J, Beuscart R, Djiane J, Demaille A: Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res 1988 (48): 6429–6433

    PubMed  CAS  Google Scholar 

  42. Foekens JA, Portengen H, Janssen M, Klijn JGM: Insulin-like growth factor 1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer. Cancer 1989 (63): 2139–2147

    Article  PubMed  CAS  Google Scholar 

  43. Peyrat J-P, Bonneterre J, Laurent JC, Louchez MM, Amrani S, Leroy-Martin B, Vilain MO, Delobelle A, Demaille A: Presence and characterization of insulin-like growth factor-1 receptors in human benign breast disease. Eur J Cancer Clin Oncol 1988 (24): 1425–1431

    Article  PubMed  CAS  Google Scholar 

  44. Klijn JGM, Foekens JA: Epidermal growth factor receptors (EGF-R) in breast cancer. Ann Oncol 1990 (1): accepted for publication

    Google Scholar 

  45. Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal-growth factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987 (i): 1398–1402

    Google Scholar 

  46. Harris AL, Nicholson S: Epidermal growth factor receptors in human breast cancer. In: Lippman ME, Dickson RB (eds) Breast Cancer: Cellular and Molecular Biology. Kluwer Academic Publishers, Boston 1988 pp 93–119

    Chapter  Google Scholar 

  47. Macias A, Azavedo E, Hägerström T, Klintenberg C, Perez R, Skoog L: Prognostic significance of the receptor for epidermal growth factor in human mammary carcinomas. Anticancer Res 1987 (7): 459–464

    PubMed  CAS  Google Scholar 

  48. Grimaux M, Romain S, Remvikos Y, Martin PM, Magdelénat H: Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res Treatm 1989 (14): 77–90

    Article  CAS  Google Scholar 

  49. Coombes RC, Murray P, Lugmani Y: The prognostic significance of transcripts for transforming growth factor alpha and beta and epidermal growth factor receptor in primary breast cancer. Eur J Cancer Clin Oncol 1990 (26): February issue, abstr 49 of Second International Symposium on Hormonal Manipulation of Cancer 1990

    Google Scholar 

  50. Nicholson S, Sainsbury JRC, Halcrow P, Chambers P, Farndon JR, Harris AL: Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1989 (i): 182–185

    Article  Google Scholar 

  51. Harris AL: Epidermal growth factor receptor: a marker of early relapse in breast cancer: interactions with Neu. Eur J Cancer Clin Oncol 1989 (26): February issue, abstr 29 of Second International Symposium on Hormonal Manipulation of Cancer 1990

    Google Scholar 

  52. Dickson RB, Lippman ME: Control of human breast cancer by estrogen, growth factors, and oncogens. In: Lippman ME, Dickson R (eds) Breast Cancer: Cellular and Molecular Biology. Kluwer Academic Publishers, Boston 1988 pp 119–167

    Chapter  Google Scholar 

  53. Reubi JC, Maurer R, von Werder K, Torhorst J, Klijn JGM, Lamberts SWJ: Somatostatin receptors in human endocrine tumors. Cancer Res 1987 (47): 551–558

    PubMed  CAS  Google Scholar 

  54. Papotti M, Macri L, Bussolati G, Reubi JC: Correlative study on neuro-endocrine differentiation and presence of somatostatin receptors in breast carcinomas. Int J Cancer 1989 (43): 365–369

    Article  PubMed  CAS  Google Scholar 

  55. Reubi JC, Waser B, Foekens JA, Klijn JGM, Lamberts SWJ, Laissue J: Evaluation of somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography. Int J Cancer 1990 (in press)

    Google Scholar 

  56. Reubi JC, Torhorst J: Relationship between somatostatin, EGF-and steroid-hormone receptors in breast cancer. Cancer 1989 (64): 1254–1260

    Article  PubMed  CAS  Google Scholar 

  57. Setyono-Han B, Henkelman MS, Foekens JA, Klijn JGM: Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 1987 (47): 1566–1570

    PubMed  CAS  Google Scholar 

  58. Szende B, Lapis K, Redding TW, Srkalovic G, Schally AV: Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin. Breast Cancer Res Treatm 1989 (14): 307–314

    Article  CAS  Google Scholar 

  59. Baildam AD, Howell A, Barnes DM, Turnbull L, Sellwood RA: The expression of milk fat globule antigens within human mammary tumours: relationship to steroid hormone receptors and response to endocrine treatment. Eur J Cancer Clin Oncol 1989 (25): 459–467

    Article  PubMed  CAS  Google Scholar 

  60. Fulton AM, Ownby HE, Frederick J, Brennan MJ: Relationship of tumor prostaglandin levels to early recurrence in women with primary breast cancer: clinical update. Invasion Metastasis 1986 (6): 83–94

    PubMed  CAS  Google Scholar 

  61. Pacheco MM, Brentani MM, Franco EL, Fontelles JA, Chamone DF, Marques LA: Plasminogen activator expression and steroid hormone receptors in female breast cancer: a multifactorial study. Int J Cancer 1988 (41): 798–804

    Article  PubMed  CAS  Google Scholar 

  62. Hennipman A, van Oirschot A, Smits J, Rijksen G, Staal GEJ: Tyrosine kinase activity in breast cancer, benign breast disease and normal breast tissue. Cancer Res 1989 (49): 516–521

    PubMed  CAS  Google Scholar 

  63. Silva MC, Rowlands MG, Dowsett M, Gusterson B, McKinna JA, Fryatt I, Coombes RC: Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Res 1989 (49): 2588–2591

    PubMed  CAS  Google Scholar 

  64. Kuhajda FP, Piantadosi S, Pasternack GR: Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 1989 (321): 636–641

    Article  PubMed  CAS  Google Scholar 

  65. Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, Paolucci F, Pau B, Rasmussen BB, Rose C: Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 1989 (49): 6008–6014

    PubMed  CAS  Google Scholar 

  66. Spyratos F, Maudelonde T, Brouillet J-P, Brunet M, Defrenne A, Andrieu C, Hacene K, Desplaces A, Rouëssé J, Rochefort H: Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet 1989 (ii): 1115–1118

    Article  Google Scholar 

  67. Namer M, Ramaioli A, Etienne MC, Fontana JC, Lapalus F, Hery M, Milano G: Prognostic value of total cathepsin D in breast cancer. Eur J Cancer Clin Oncol 1990 (26): February issue, abstr 129 of Second International Symposium on Hormonal Manipulation of Cancer 1990

    Google Scholar 

  68. Jäger W, Merkle E, Maloth E, Lang N: Cathepsin D in breast cancer cytosol -follow-up after 18 months. Eur J Clin Oncol 1990 (26): February issue, abstr 130 of Second International Symposium on Hormonal Manipulation of Cancer 1990

    Google Scholar 

  69. Henry JA, McCarthy AL, Angus B, Westley BR, May FEB, Nicholson S, Cairns J, Harris AL, Home CHW: Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. Cancer 1990 (65): 265–271

    Article  PubMed  CAS  Google Scholar 

  70. Foekens JA, Rio M-C, Seguin P, van Putten WLJ, Fauque J, Nap M, Klijn JGM, Chambon P: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 1990 (50): in press (June issue)

    Google Scholar 

  71. Mackay J, Steel CM, Elder PA, Forrest APM, Evans HJ: Allele loss on short arm of chromosome 17 in breast cancers. Lancet 1988 (ii): 1384–1385

    Article  Google Scholar 

  72. Devilee P, Pearson PL, Comelisse CJ: Allele losses in breast cancer. Lancet 1989 (i): 154

    Article  Google Scholar 

  73. Clark GM, Dressier LG, Owens MA, Pounds G, Oldaker T, McGuire WL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989 (320): 627–633

    Article  PubMed  CAS  Google Scholar 

  74. Ali IU, Lidereau R, Callahan R: Heterogeneity of genetic alterations in primary human breast tumors. In: Lippman ME, Dickson R (Eds) Breast Cancer: Cellular and Molecular Biology. Kluwer Academic Publishers, Boston 1988 pp 25–49

    Chapter  Google Scholar 

  75. Callahan R: Genetic alterations in primary breast cancer. Breast Cancer Res Treat 1989 (13): 191–203

    Article  PubMed  CAS  Google Scholar 

  76. Merkel DE, McGuire WL: Oncogenes and cancer prognosis. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important Advances in Oncology. JB Lippincott Company, Philadelphia 1988 pp 103–116

    Google Scholar 

  77. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 (235):177–182

    Article  PubMed  CAS  Google Scholar 

  78. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 (244): 707–712

    Article  PubMed  CAS  Google Scholar 

  79. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989 (7): 1120–1128

    PubMed  CAS  Google Scholar 

  80. Van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R: Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988 (319): 1239–1245

    Article  PubMed  Google Scholar 

  81. Zeillinger R, Kury F, Czerwenka K, Kubista E, Sliutz G, Knogler W, Huber J, Zielinski C, Reiner G, Jakesz R, Staffen A, Reiner A, Wrba F, Spona J: HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 1989 (4): 109–114

    PubMed  CAS  Google Scholar 

  82. Wright C, Angus B, Nicholson S, Sainsbury JRC, Cairns J, Gullick WJ, Kelly P, Harris AL, Home CHW: Expression of C-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989 (49): 2087–2090

    PubMed  CAS  Google Scholar 

  83. Adnane J, Gaudray P, Simon M-P, Simony-Lafontaine J, Jeanteur P, Theillet C: Proto-oncogene amplification and human breast tumor phenotype. Oncogene 1989 (4): 1389–1395

    PubMed  CAS  Google Scholar 

  84. Tsuda H, Hirobashi S, Shimosato Y et al: Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and C-erbB-2/ear-1. Cancer Res 1989 (49): 3104–3108

    PubMed  CAS  Google Scholar 

  85. Duffy MJ: Biochemical markers as prognostic indices in breast cancer. Clin Chem 1990 (36): 188– 191

    PubMed  CAS  Google Scholar 

  86. Meyer JS: Cell kinetics in selection and stratification of patients for adjuvant therapy of breast carcinoma. NCI Monogr 1986 (1): 25–28

    PubMed  Google Scholar 

  87. Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Bonadonna G: Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol 1989 (25): 1165– 1171

    Article  PubMed  CAS  Google Scholar 

  88. Tubiana M, Pejovic MH, Koscielny S, Chavaudra N, Malaise E: Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast ccancer. Int J Cancer 1989 (44): 17–22

    Article  PubMed  CAS  Google Scholar 

  89. Courdi A, Héry M, Dahan E, Gioanni J, Abbes M, Monticelli J, Ettore F, Moll J-L, Namer M: Factors affecting relapse in node-negative breast cancer. A multivariate analysis including the labeling index. Eur J Cancer Clin Oncol 1989 (25): 351–356

    Article  PubMed  CAS  Google Scholar 

  90. Charpin C, Andrac L, Vacheret H, Habib MC, Devictor B, Lavaut MN, Toga M: Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections. Cancer Res 1988 (48): 4368–4374

    PubMed  CAS  Google Scholar 

  91. Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JFR, Blarney RW, Nicholson Rl: Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 1989 (59): 943–947

    Article  PubMed  CAS  Google Scholar 

  92. Hug V, Thames H, Bentzen S: Predictors of hormone response for patients with ER-unknown breast tumors. Br J Cancer 1989 (59): 421–425

    Article  PubMed  CAS  Google Scholar 

  93. Sacannijotti G, Bonadonna G: The pathologist and the clinical oncologist: a new effective partnership in assessing tumor prognosis. Eur J Cancer Clin Oncol 1989 (25): 585–598

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrine Oncology, Dr. Daniël den Hoed Cancer Centre, Groene Hilledijk 301, 3075 AE, Rotterdam, The Netherlands

    Jan G. M. Klijn & John A. Foekens

Authors
  1. Jan G. M. Klijn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John A. Foekens
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Ospedale Civico, via Tesserete 46, 6900, Lugano, Switzerland

    A. Goldhirsch

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Klijn, J.G.M., Foekens, J.A. (1990). Prognostic Factors in Breast Cancer. In: Goldhirsch, A. (eds) Endocrine Therapy of Breast Cancer IV. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75948-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-75948-2_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-75950-5

  • Online ISBN: 978-3-642-75948-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation